Clinical trial
A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk…
NCT01122368 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT01122368 |
|---|---|
| Title | A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects |
| Official title | An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Double-blind Study |
| Acronym | INTENSE |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mycoses |
| Intervention type | Drug |
| Interventions | micafungin, placebo |
| Enrollment | 252 |
| Start date | Jul 13, 2010 |
| Primary completion | Dec 15, 2011 |
| Completion | Dec 15, 2011 |
| First posted | May 13, 2010 |
| Last update posted | Nov 19, 2024 |
| Countries | Austria, Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Romania, Spain and 3 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: